Global opioid use disorder market is estimated to be valued at US$ 3.24 Bn in 2023, and is expected to exhibit a CAGR of 8.7% during the forecast period (2023-2030).
Report Coverage |
Report Details |
Base Year: |
2022 |
Market Size in 2023: |
US$ 3.24 Bn |
Historical Data for: |
2018 to 2021 |
Forecast Period: |
2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: |
8.70% |
2030 Value Projection: |
US$ 5.8 Bn |
Figure 1. Global Opioid Use Disorder Market Share (%), By Drug Type, 2023
Opioids are naturally or synthetically made in laboratories to interact with opioid receptors on the nerve cells in the body and brain, and helps in reducing pain. These are class of drugs that include prescription pain relievers, synthetic opioids, and heroin. Prescription opioids are used to treat acute pain such as recovering from injury or post-surgery, chronic pain, active-phase cancer treatment, palliative care, and end-of-life care. Many people rely on prescription opioids to manage their conditions under the care of a physician. Opioid use disorder is a chronic lifelong disorder, with serious potential consequences including disability, relapses, and death.
Methadone is a full opioid agonist that works by binding to the mu-opioid receptors in the brain to relieve cramps and withdrawal symptoms. It comes in a liquid form that must be administered daily under medical supervision. This makes it challenging for some patients but also reduces abuse and diversion risks. Buprenorphine is a partial opioid agonist that provides pain relief without the typical euphoria. Naltrexone is an opioid antagonist that blocks the effects of other opioids. The oral form must be taken daily while the injectable extended-release version lasts for monthly doses.
Market Dynamics
Global opioid use disorder market growth is driven by increasing product launches by key market players to expand their product portfolio. For instance, in December 2021, Sandoz, a global leader in generic and biosimilar medicines, announced the U.S. launch of its authorized generic of Narcan (naloxone hydrochloride) Nasal Spray 4mg that is used to reverse opioid overdose. It is available to people in the U.S. via retail pharmacies and institutions including hospitals.
Key features of the study:
- This report provides an in-depth analysis of the global opioid use disorder market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global opioid use disorder market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
- The key companies covered as a part of this study include Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc, Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Hikma Pharmaceuticals PLC, Camurus AB, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., Purdue Pharma LP, Alvogen, Faran Shimi Pharmaceutical, Novartis AG, Emplicure AB, and MODASA Pharmaceuticals Pvt. Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global opioid use disorder market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing global opioid use disorder market
Detailed Segmentation:
- By Drug Type:
- Buprenorphine
- Methadone
- Naltrexone
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- Indivior PLC
- Alkermes
- Orexo AB
- Titan Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals
- BioDelivery Sciences International Inc.
- Viatris Inc.
- Hikma Pharmaceuticals PLC
- Camurus AB
- Sun Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals LLC.
- Purdue Pharma LP
- Alvogen
- Faran Shimi Pharmaceutical
- Novartis AG
- Emplicure AB
- MODASA Pharmaceuticals Pvt. Ltd.